AstraZeneca’s chief medical officer, Ann Taylor, added that the number of blood clots reported among the 17 million people who received the vaccine was “lower than the hundreds of cases that would be expected among the general population.” There were 15 events of deep vein thrombosis and 22 cases of pulmonary embolism in that group, “much lower than would be expected to occur naturally,” the company added.
“The nature of the pandemic has led to increased attention in individual cases and we are going beyond the standard practices for safety monitoring of licensed medicines in reporting vaccine events, to ensure public safety,” Taylor said in a statement.earlier this week, which said there was currently “no indication” of a link between the vaccine and blood clots, and that the benefits of the jab outweighed any risks.
“The position of EMA’s safety committee ... is that the vaccine’s benefits continue to outweigh its risks and the vaccine can continue to be administered while investigation of cases of thromboembolic events is ongoing,” the agency said. The AstraZeneca vaccine has struggled with a series of public relations setbacks during its testing and rollout phases. Clinical trials showed it has a lower efficacy rate than other leading vaccines, namely the Moderna and Pfizer shots, butStill, in some countries, hundreds of thousands of doses
HuffPostPol Not sure I trust this.